We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Circulating Tumor DNA Following Surgery Predicts Bladder Cancer Recurrence

By LabMedica International staff writers
Posted on 01 Jul 2021
A blood test that detects circulating tumor DNA (ctDNA) predicts risk of bladder cancer recurrence following surgery and can be used to guide precision treatment of the disease. More...


Worldwide, there were approximately 573,000 cases of bladder cancer with about 212,000 deaths in 2020. Surgery, which is the usual first treatment for the disorder, often leaves behind some cancer cells, molecular residual disease (MRD), which can regenerate the tumor. Rather than just waiting to see if the cancer returns following surgery, researchers are developing minimally invasive approaches for detection of MRD after surgery to identify patients who are at risk for metastatic relapse.

In this regard, circulating tumor DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse. This follows from studies showing that liquid biopsy analysis of circulating cell-free DNA (cfDNA) from peripheral blood could be a valuable diagnostic tool in oncology, since sample collection is quick and minimally invasive. In cancer patients, cfDNA consists in part of cancer-derived circulating tumor DNA (ctDNA), and it has been shown that tumor-related genetic and epigenetic alterations can be detected by analyzing cfDNA in cancer patients. As a consequence, cfDNA analysis holds great promise for precision oncology and personalized therapies, and is currently being evaluated in a broad range of clinical studies.

To test for MRD in bladder cancer patients following surgery, investigators at Queen Mary University of London (United Kingdom) used a ctDNA liquid biopsy approach to evaluate treatment outcomes in 581 individuals who were enrolled in a randomized phase III trial and a phase II study, which investigated whether the drug atezolizumab could reduce cancer recurrence in high-risk muscle-invasive urothelial carcinoma.

Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). It is used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). The drug’s most common adverse side effects include urinary tract infection, fatigue, decreased appetite, nausea, and infections.

Results obtained by this study revealed that patients with ctDNA-positive blood tests after surgery were at higher risk of cancer recurrence than those who were ctDNA-negative. Treatment with atezolizumab did not significantly improve disease-free survival (DFS) or overall survival (OS) in the whole study population; however, in the ctDNA-positive subgroup of patients evaluated in this study, treatment with atezolizumab compared with observation alone significantly improved DFS and OS. The outcomes in patients who were ctDNA-negative did not appear to differ whether they received atezolizumab or not.

First author Dr. Tom Powles, professor of genitourinary oncology at Queen Mary University of London, said, "These novel findings demonstrate ctDNA as a marker for residual disease and response to atezolizumab. We also found ctDNA measurement to be more accurate than traditional radiology at identifying disease relapse. These findings may change our understanding of post-surgical cancer care and, if validated in this setting as well as across tumor types, they may also change clinical practice."

The study was published in the June 16, 2021, online edition of the journal Nature.

Related Links:
Queen Mary University of London


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.